Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Shutdown Plans For 2015: Same As 2013, But With More People

This article was originally published in The Pink Sheet Daily

Executive Summary

'Limited activities related to user fee funded programs' will continue if Congress does not pass a short-term funding measure by Oct. 1.

You may also be interested in...



FDA Shutdown Hangover Hurts Biosimilars, May Benefit Some ANDAs

As normal operations – and normal budget worries – resume, the agency has some meetings to reschedule.

Bayer’s Adempas Overcomes FDA Dosing Concerns To Win Approval

Riociguat becomes the first therapy indicated for chronic thromboembolic pulmonary hypertension in the U.S. Labeling includes Bayer’s recommended starting and maximum doses but provides the option for a lower starting dose in patients who may not tolerate the hypotensive effects, a concern for agency reviewers.

Pfizer’s Duavee Approved For Hot Flashes, Osteoporosis Prevention

FDA cleared the single pill combining conjugated estrogens with bazedoxifene, a novel selective estrogen receptor modulator, for two indications but issued a “complete response” letter for use in vulvar and vaginal atrophy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel